MMJ « AGORACOM Small-cap Investor Relations Blog

Posts Tagged ‘MMJ’

Tetra Bio-Pharma $TBP.ca Accelerates its European Drug Registration Activities $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:24 AM on Tuesday, September 11th, 2018

Announced today that it is accelerating the submission of a pre-marketing application for the registration of its cannabis drugs PPP001 and PPP005 under Directive 2001/83/EC of the European Parliament and of the Council.Â
This directive provides Tetra Bio-Pharma with the legal and regulatory framework needed to submit its pre-marketing application for its cannabis drugs

PPP001 and PPP005 Eligible for Marketing Approval

ORLEANS, Ontario, Sept. 11, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or theÂ “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it is accelerating the submission of a pre-marketing application for the registration of its cannabis drugs PPP001 and PPP005 under Directive 2001/83/EC of the European Parliament and of the Council.

This directive provides Tetra Bio-Pharma with the legal and regulatory framework needed to submit its pre-marketing application for its cannabis drugs.Â According to Dr. Guy Chamberland, Interim CEO and CSO, â€œthe corporation has performed its own clinical trials and has sufficient quality and clinical trial data to initiate the application for the registration of PPP001 and PPP005 under the Directive 2001/83/EC.Â Tetra intends to pursue a Full Market Authorisation since it has a dossier supporting the medicinal productâ€™s quality, safety, and efficacy.â€

All of Tetraâ€™s clinical trials were performed with the same quality of evidence required by the National Competent authorities approving medicines/drugs.Â Tetra has completed several well-designed safety, pharmacodynamic and pharmacokinetic studies in healthy volunteers and also has two ongoing, well-designed clinical trials in patients.Â These trials are all double-blind, randomized and placebo controlled.

AboutÂ Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001 and/or PPP005 by the European Medicines Agency, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine	Stephanie Engel
514-288-8500 ext. 226	416-425-9143 ext. 209
[email protected]	[email protected]

Tags: #smallcapstocks, $TSXV, CBD, CSE, MMJ
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Accelerates its European Drug Registration Activities $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Secures CBD Supply Agreement for Genacol Partnership $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:17 AM on Wednesday, September 5th, 2018

Announced that it has secured a CBD supply agreement with True North Cannabis in Alberta, Canada.Â
Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation which will be commercialized under the previously announced partnership with Genacol

ORLEANS, Ontario, Sept. 05, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that it has secured a CBD supply agreement with True North Cannabis in Alberta, Canada.Â Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation which will be commercialized under the previously announced partnership with Genacol.

Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create these innovative products for Genacol.Â Tetra Bio-Pharma will work with the appropriate regulatory agencies to gain marketing authority within Genacolâ€™s international sales network where their brand products are available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. According to industry statistics the market for topical pain relief products exceeds $2.5 billion. The products are expected to be launched in 2019.

â€œWe are very pleased to secure a competitive supply agreement with True North Cannabis as Tetra is committed on bringing innovative cannabinoid products to market,â€ says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. Â â€œTrue North Cannabis has built a state-of-the-art facility in Alberta which will provide the highest quality CBD for Tetra, at a competitive price, to develop innovative products in partnership with Genacol.Â Price to consumers is a critical aspect for the viability of a commercial product in the self-care health market.Â At Tetra Bio-Pharma we are focused on becoming a global leader in the development of cannabinoid derived prescription and natural health products.â€

â€œTrue North Cannabis is pleased to enter into a commercial relationship to supply hemp-based CBD to Tetra Bio-Pharma,â€ Shayne Hamilton, Chief Executive Officer of True North Cannabis commented.Â â€œOur business leverages the size and scale of the industrial hemp crop in Canada to provide a competitively priced, reliable source of CBD.Â Tetra Bio-Pharmaâ€™s vast experience in pharmaceutical product development, along with Genacolâ€™s robust distribution footprint, presents True North Cannabis a unique opportunity to market our product.â€

AboutÂ Tetra Bio-Pharma
Tetra Bio-PharmaÂ (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with aÂ Health CanadaÂ approved, andÂ FDAÂ reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline ofÂ Bio Pharmaceuticals,Â Natural HealthÂ and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do,Â Tetra Bio-PharmaÂ is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit:Â www.tetrabiopharma.com

AboutÂ True North Cannabis
True North Cannabis (TNC) is a Canadian hemp harvest service provider with a core focus on facilitating the supply of bulk, extract-ready, hemp-based CBD.

With a grower-focused service model, TNC supports industrial hemp growers across Canada to effectively commercialize the cannabinoid content from their harvest. Â By providing access to state of the art infrastructure and hemp chaff expertise, TNC manages the unique challenges in bridging broad acre agriculture and the Cannabis industry.

For more information visit:Â www.truenorthcannabis.com

Source: Tetra Bio-Pharma

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, and the success of its natural health products development and commercialization strategies, Â and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine
[email protected]
514-288-8500 ext. 225
416-425-9143 ext. 225

Tags: #smallcapstocks, $TSXV, CBD, CSE, MMJ
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Secures CBD Supply Agreement for Genacol Partnership $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America $MCOA Provides Update on CBD Hemp Joint Venture Farming Project in New Brunswick Canada $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:35 AM on Thursday, August 30th, 2018

15233 mcoa

Provide an update on their CBD hemp farming joint venture in New Brunswick, Canada
Dryer Installation – Drying of the biomass is an important first step in the extraction of the cannabinoids from the hemp plant

ESCONDIDO, Calif., Aug. 30, 2018Â â€“Â MARIJUANA COMPANY OF AMERICA INC. (â€œMCOAâ€ or the â€œCompanyâ€) (OTC: MCOA), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group Inc. (CSE: GHG) (OTC:GBHPF) (FRANKFURT: GHG) (the â€œPartnersâ€) are pleased to provide an update on their CBD hemp farming joint venture in New Brunswick, Canada (the â€œProjectâ€).

Dryer Installation
Drying of the biomass is an important first step in the extraction of the cannabinoids from the hemp plant. The partners are pleased to announce that the Projectâ€™s industrial scale dryer from Cann Systems was delivered last week and has now been installed.

The dryer holds multiple bins of material, for a total processing capacity of just over one tonne of fresh hemp biomass per load. Initial testing is in progress and will be completed by the end of this week. Once the biomass has been dried from this yearâ€™s harvest, it will be stored until the implementation of the Cannabis Act on Oct. 17, 2018, at which time the biomass can be legally sold for extraction. Health Canada has recently issued a new Class Exemption to the Industrial Hemp Regulations that allows hemp cultivation license holders to legally harvest, dry and store flowers, leaves and branches prior to the passage of the Cannabis Act. Management is currently in discussions with potential offtakers for selling the dried biomass in bulk, as well as exploring potential strategies for toll extraction and the marketing and distribution of processed and refined oils.

Innovation in the Hemp Industry
It is now nearing harvest time at the New Brunswick Hemp Project. To maximize profit, it is important to harvest as much of the higher CBD content flowers and leaves as possible, without undue amounts of the low to no CBD straw (the stalk). This yearâ€™s drought has complicated matters as the hemp plants have tended to be shorter than usual, and the weeds are taller as they were able to get a head start before the hemp began growing, although the hemp is still displaying very healthy and weighty inflorescence. These issues that are perceived as problems at they occur, may benefit the hemp plants which tend to produce more biomass as a result of stress from competition with weeds and the effects of the drought.

In order to succeed in the hemp industry, a certain amount of ingenuity and innovation is required more often than not. Our farming group is a good example of this ingenuity. Sometimes repurposing existing equipment on hand will work to achieve the required result. To combat the higher than normal weed height and to maximize the value of the harvest by taking just the most valuable parts of the hemp plant, a small harvesting trial was conducted by one of our farmers using an OXBO bean harvester. The bean harvester is able to strip the plant of all leaves and inflorescence, while picking up very little straw, which is ideal for this yearâ€™s crop. Based on the positive results of this trial, the bean harvester will be used to complete the harvest of the entire 125 acres of hemp cultivated under the joint venture project with MCOA this year.

In non-drought years, other harvesting tools will be required and the innovative farmers of our group have already begun strategizing on potential solutions that will be applicable next year when the Partners move forward with an aggressive expansion strategy to significantly increase CBD acreage as well as fully exploit the whole hemp plant and process the straw for industrial applications.

New Research Collaboration
The drought in northeast New Brunswick has not affected all fields uniformly. One of our fields is reported by DAAF field agrologists as â€œone of the finest of the provinceâ€. Aside from the obvious economic benefit in terms of increased yields, this field offers the opportunity to contrast high and low performing plants of a given variety in the same location, shedding some light on the role of plant nutrition in explaining the performance of hemp plants. Dr. Ron Smith from University of New Brunswick will spearhead a research project focused on the issue. The Partners and the National Research Council have committed to provide financial support for the study.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name â€œhempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets andÂ opportunities in this segment mature and develop.

About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FRANKFURT: GHG), is headquartered in Vancouver, British Columbia, Canada, with base operations in Montreal and Los Angeles. The Company is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial hemp products utilizing the processing of the whole hemp plant, as envisioned in the Companyâ€™s Hemp Agro-Industrial Zone (HAIZ) strategy.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Companyâ€™s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: $TSXV, CSE, MMJ
Posted in Medical Marijuana Stocks | Comments Off on Marijuana Company of America $MCOA Provides Update on CBD Hemp Joint Venture Farming Project in New Brunswick Canada $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Adds New Marketing Vice-President $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:18 AM on Thursday, August 30th, 2018

Announced that Mr.Â Steeve NeronÂ has joined Tetra Bio-Pharma as Vice-President, Marketing, effective August 20, 2018
He will be responsible for all Tetra Bio-Pharma and Tetra Natural Heath marketing activities

ORLEANS, Ontario, Aug. 30, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Mr.Â Steeve NeronÂ has joined Tetra Bio-Pharma as Vice-President, Marketing, effective August 20, 2018. He will be responsible for all Tetra Bio-Pharma and Tetra Natural Heath marketing activities.

Steeve has more than 32Â yearsâ€™ experience in the pharmaceutical industry with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, womenâ€™s health, asthma/COPD, OTC and dermatology where challenging the reimbursement landscape factored prominently in his role. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada, formerly Valeant.

Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).

â€œI am very proud to addÂ SteeveÂ to our senior management team. His vast experience will enable Tetra to achieve its high standards in executional excellence,â€ saysÂ Richard Giguere Executive Vice-President, Commercial Operations.

â€œI am very excited to have the opportunity of contributing my pharmaceutical marketing knowledge within the growing cannabinoid-based products sector,â€ said Steeve Neron. â€œTetra has set the bar high from a clinical development standpoint and this is a critical factor to maximize the therapeutic potential of cannabis.â€

For more information visit:Â www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine
[email protected]
514-288-8500 ext. 225
416-425-9143 ext. 225

Tags: #smallcapstocks, $TSXV, CSE, MMJ
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Adds New Marketing Vice-President $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Announces Supply Agreement with Kief #Cannabis $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:41 AM on Wednesday, August 29th, 2018

Company has signed a wholesale supply agreementwith Manitoba-based, late-stage ACMPR applicant, Kief Cannabis Company Ltd.
Under the terms of the Supply Agreement, Namaste will purchase bulk cannabis products under the Company’s wholly-owned subsidiary, Cannmart Inc. to offer in its online platform

VANCOUVER, Aug, 29, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has signed a wholesale supply agreement (the “Supply Agreement”) with Manitoba-based, late-stage ACMPR applicant, Kief Cannabis Company Ltd. (“Kief Cannabis” or “kiefcannabis.ca”). Under the terms of the Supply Agreement, Namaste will purchase bulk cannabis products under the Company’s wholly-owned subsidiary, Cannmart Inc. (“Cannmart”) to offer in its online platform.

Kief Cannabis is focused on developing high-quality artisan-crafted cannabis products with a specific focus on the best plant genetics and a refined production process that is designed to deliver high-grade, small-batch craft product. Kief Cannabis will focus on the high-end recreational market with premium quality cannabis. Through the Supply Agreement with Namaste, Kief Cannabis will position in itself for national exposure by offering its products through Cannmart’s online marketplace and in having their products for sale along with other leading Canadian cultivators who are participating in Namaste’s platform.

With NamasteMD’s (“NamasteMD.com“) patient database growing at an exponential rate, and with Cannmart’s sales license imminent, the Company has successfully secured guaranteed supply through agreements with its cultivation partners. Due to its rapid and accelerating growth rate, NamasteMD’s clinic team has expanded to accommodate the influx of patient consultations. Namaste has already established itself as the largest global online marketplace for cannabis consumption devices and has over 1.5 Million customers globally. The Company has developed and uses industry leading e-commerce technology including on-site AI through its wholly owned subsidiary, Findify AB (“Findify.io”), that personalizes the online user experience for every customer.

Cannmart’s platform, following the same strategy will offer patients access to the largest variety of cannabis products sourced from multiple vendors in a single location. With innovations like NamasteMD, Findify and Cannmart’s online platform, the Company has created a fully-integrated patient experience from prescription to delivery. Cannmart will be one of the first online retailers to offer same-day delivery service through its partner, Pineapple Express Delivery Inc. (“Pineapple Express”), starting with the Greater Toronto Area (GTA) and expanding across the country. This Supply Agreement represents further progress in Namaste positioning itself as Canada’s leader for cannabis e-commerce and technology. The Company has received immense support from its cultivation partners that validate Namaste’s platform and strategy.

Management Commentary

Jesse Denton, CEO of Kief Cannabis comments: “Namaste has positioned itself very strategically to become Canada’s top cannabis retailer online and their business model is supported by their success in e-commerce both in Canada and international markets. I’m very pleased for Kief Cannabis to be aligned with such a major player, and look forward to a long-term working relationship with the Namaste team.”

Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to announce this Supply Agreement with Kief Cannabis. We’ve spent significant time in discussion with their team and believe strongly in our ability to market and sell craft cannabis brands in our platform. We believe that consumers should have access to the best selection of high quality product and we’re focused on building relationships with craft brands like Kief Cannabis who will create more value for our patients online.

Ultimately, everything we’re doing is focused on creating a personalized and amazing user experience. All of the technology we’ve developed has been centered around this concept. The more value we can bring to our customers, whether through NamasteMD, AI integrations or the best possible customer service, Namaste has years of experience operating in the online market and that is what I believe sets us apart from our competitors.

We’re also very proud that our cultivator partners across the country see value in Namaste’s platform and marketplace. We believe that the online market for medical and recreational cannabis will evolve rapidly in Canada and that Namaste is well-positioned with extensive expertise to be the number one online platform for everything cannabis not only in Canada but globally.”

About Kief Cannabis

Kief Cannabis was established as a corporation in December of 2013 under the laws of the Province of Manitoba with the goal of producing and delivering craft-style cannabis to the Canadian marketplace. On March 16, 2018, Health Canada provided a Confirmation of Site Readiness letter to Kief Cannabis, and the company has been recognized by the Liquor and Gaming Authority of Manitoba (to be renamed the Liquor, Gaming and Cannabis Authority of Manitoba) as an upcoming supply chain within the Province of Manitoba.

Kief Cannabis is comprised of passionate and determined individuals who will strive: i) to collectively provide exceptionally high quality small-batch craft cannabis strains to recreational users across Canada; and ii) to create an environmentally-friendly, socially responsible and Canadian-owned company. The initial product line will consist of internationally exclusive and rare strains of cannabis and oils, with the intent to expand into vape-pens, rosins and edible products as they become legal in Canada. Kief Cannabis’ unique variety of cannabis strains will appeal to those seeking a more exclusive, premier product with a small-batch craft feel.

Kief Cannabis is currently in its Series A funding stage and intends to raise the capital needed to complete the construction of a state-of-the-art cultivation facility located in Selkirk Manitoba. Once completed, Kief Cannabis shall utilize refined procedures throughout the entire production process to develop exceptionally high-grade products for its end-users.

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms.Â Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to itsÂ shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 604-355-6100

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press

View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-announces-supply-agreement-with-kief-cannabis-300704020.html

SOURCE Namaste Technologies Inc.

Tags: #smallcapstocks, $TSXV, Cannabis, CSE, MMJ, Vapes, Vaping
Posted in Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Supply Agreement with Kief #Cannabis $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Namaste $N.ca $NXTTF announces recreational cannabis market strategy $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:06 AM on Tuesday, August 28th, 2018

Announced itsÂ new corporateÂ strategyÂ relatedÂ to its position in the Canadian recreational cannabis marketplace
Due toÂ muchÂ uncertainty surrounding both federal and provincial roll-outs of recreational cannabis, Namaste remained focused solely on the medical cannabis market until such time that a more transparent framework was established

VANCOUVER, Aug. 28, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announceÂ itsÂ new corporateÂ strategyÂ relatedÂ to its position in the Canadian recreational cannabis marketplace. Due toÂ muchÂ uncertainty surrounding both federal and provincial roll-outs of recreational cannabis, Namaste remained focused solely on the medical cannabis market until such time that a more transparent framework was established. Fast forward to today and it is clearly evident that there has been significant progress made with regards to the rules and regulations outlining the sale and distribution of recreational cannabis. As such, Namaste has made the decision to take a more proactive approach in an attempt to capitalize on several key areas of the recreational market.

FurtherÂ to recent updates from the Provincial Government of Ontario, Namaste is extremely confident that many ofÂ its technologyÂ assets will lend themselves to improving the security and distribution of recreational cannabis online and in provincially operated dispensaries. Namaste’s platforms, including its exclusive partnership withÂ YPB Group Ltd. (“YPB”) (ASX: YPB), have the potential to provide far superior authentication and security forÂ provinciallyÂ approved cannabis products. In addition, the Company’s age and identity verification, with exclusive rights to its facial recognition technology, could help provide a much safer protocol for online retail platforms.Â ThroughÂ NamasteMD, the Company has developed and acquired cutting-edge age and identity verification technology which is already in use in Namaste’s platform, that would provide significant value to all consumers, through all the varying distribution channels across Canada. Namaste would like to reinforce that both platforms are already proven and in operation and would be available for immediate deployment within these applications.

In addition to these valuable authentication protocols, Namaste has also identified the need for its global customers to have confidence in the products they are purchasing, and for vendors to have access to granular data on their end-users.Â As such, Namaste has introduced YPB’s solutions across its network of manufacturers, including Canadian Licensed Producers, to help bring certainty of authenticity and supply chain transparency to the entire legal cannabis industry globally. This coalition furthers Namaste’s agenda in providing leading technology platforms for its global marketplace and for enhancing the user experience for its customers.

With YPB having recently signed 3 new customers, there is little doubt that this technology brings value to those who adopt YPB’s technology. Namaste believes YPB’s technology could provide a far superior solution to all provinces, especially considering the Ontario Provincial Governments decision regarding online dispensaries. The use of product QR codes would allow those who adopt the technology the ability to not only verify the authenticity of a cannabis product being provincially approved, but also provide valuable product information, including strain data and origin.

Namaste will be initiating the development of a private-label line of cannabis products through its Licensed Producer partners that will include a unique offering of premium strains and products that will be targeted to both medical and recreational markets. By securing numerous agreements with a multitude of Licensed Producers, Namaste has successfully guaranteed its supply channel on a going forward basis, and pending approval ofÂ Cannmart’sÂ sales license, the Company is well positioned to launch its fully-integrated marketplace by introducing cannabis sales into its online platform.

The Company will be actively pursuing opportunities in online recreational cannabis sales within provinces that permit. Through its partnerships with Licensed Producers, Namaste will offer a comprehensive online platform for recreational cannabis including integration of its various technology components that will bring significant value to Namaste and its partners. Namaste will also have the unique ability to offer other various technology integrations, including Pineapple Express Inc. (“Pineapple Express”) same-day delivery service. With the initial launch of same-day delivery in Toronto, which represents the fourth largest city in North America, Namaste eventually plans to roll-out the service across Canada and into other major markets including Vancouver and Winnipeg.

While Namaste has laid the foundation to become Canada’s leading online retailer of medicinal cannabis and will continue to focus on the medical market, the Company is now focused on expanding the scope of its platform to gain market share in the recreational space by offering the top Licensed Producer products, industry-leading technology integrations and a superior user experience.

Management Commentary

Sean Dollinger, President, and CEO of Namaste comments: “Over the past year we’ve been very quiet as it relates to the recreational cannabis industry. We have taken our time to see how the legislation progresses province by province. Although we are not a cultivator, we do see significant market share for the Company in providing highly valuable technology platforms to the recreational market. Furthermore, through strategic partnerships with Licensed Producers we will certainly be developing our own brand that will be sold through medical and recreational channels.

As we progress towards official legalization Namaste has never been better positioned to capitalize on both markets. Now that we have proven that our platform works, with the acceleration of our medical patients we can now work on utilizing our technology to become a leader in the recreational space.

We are very excited to see our strategy coming together and unfolding before our eyes. We’d like to thank all of our shareholders for their support and hope to see everyone at the Pledge Party September 12th.

About Namaste Technologies Inc.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (604) 355-6100

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

SOURCE Namaste Technologies Inc.

Tags: #smallcapstocks, $TSXV, CSE, MMJ, Vapes, Vaping
Posted in All Recent Posts, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF announces recreational cannabis market strategy $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Namaste $N.ca $NXTTF Announces Supply Agreement with GTEC Holdings $GTEC.ca $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:50 AM on Monday, August 27th, 2018

Company has signed a bulk cannabis supply agreement (the “Supply Agreement”) with GTEC Holdings Ltd.
Â Cannmart Inc. will purchase bulk cannabis flower and oil from GTEC for resale in Cannmart’s online platform

VANCOUVER, Aug. 27, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announceÂ that the Company has signed a bulk cannabis supply agreement (the “Supply Agreement”) with GTEC Holdings Ltd. (“GTEC”) (TSXV: GTEC) (OTCPK: GGTTF), whereby Namaste’s wholly owned subsidiary and Health Canada’s Access to Cannabis for Medical Purposes (“ACMPR”) late-stage applicant, Cannmart Inc. (“Cannmart”) will purchase bulk cannabis flower and oil from GTEC for resale in Cannmart’s online platform. Cannmart will be Canada’s first ACMPR Licensed Producer (“LP”) with a “sales-only” license, allowing the Company to leverage its e-commerce expertise to become Canada’s leading cannabis online retailer.

This Supply Agreement further demonstrates Namaste’s ability to secure a strong supply chain to help service Namaste’s growing list of patients, and execute on its strategy to create Canada’s largest online retail cannabis platform. GTEC is a Kelowna-based LP which owns and operates several cultivation facilities, and Namaste anticipates GTEC becoming a key supplier for Cannmart’s platform. With the upcoming roll-out of recreational cannabis and with an anticipated short-term national supply shortage, cannabis supply agreements are now more important than ever to Namaste’s long-term strategy. This Supply Agreement further demonstrates Namastes ability to secure a strong supply chain with multiple LP’s.

Namaste’s e-commerce platform and technology will continue to drive innovation that will have a major impact on the way in which patients can access medical cannabis online. Namaste’s goal is to create the most comprehensive user experience possible by personalizing product and strain recommendations through the integration of its AI technology, by providing convenient access to healthcare practitioners, and by driving cannabis sales through Cannmart.

With the recent launch of NamsteMD’s (“NamasteMD.com“)Â Google Android App, the company expects to see exponential growth having recently reached over 14,000 registered users. The continuous acceleration and strong supply channels have Namaste well-positioned to integrate cannabis sales within its e-commerce platform. The Company has been overwhelmed with support from its LP partners who see Namaste’s vision to become the global leader in online retail for all things cannabis.

Management Commentary

Norton Singhavon, Chairman and CEO of GTEC comments: “GTEC is actively pursuing long-term supply agreements with Licensed Producers whose core competencies are complementary to our own.Â Accordingly, we are very excited about our partnership with CannMart and Namaste.Â We believe that GreenTec’s ability to cultivate and market high-quality craft cannabis provides an excellent fit with Cannmart’s packaging and distribution capabilities, and Namaste’s ability to develop a robust network of medical cannabis patients”.

Sean Dollinger, President, and CEO of Namaste comments: “We have been working on securing this Supply Agreement with GTEC for several months and are thrilled to see this come together nicely. GTEC operates multiple facilities and will be launching a new production facility in Kelowna shortly. We’re pleased to have secured another strong supplier for Cannmart.

We’re expecting to receive our sales license very soon and are highly focused on expansion of our patient network and in curating a high-quality offering of cannabis products for our customers. During a time where inventory remains on shortage with many vendors, we are proud to have partners like GTEC who see value in the platform which we’ve created. Thanks to GTEC’s management team for supporting Namaste in its efforts to become Canada’s leading online cannabis retailer and we’re looking forward to a strong partnership together”

About GTEC Holdings Inc.

GTEC was founded in 2017 to capitalize on opportunities in the nascent and rapidly growing legal cannabis industry.Â GTEC is focused on growing premium quality craft cannabis in purpose-built indoor facilities.Â The Company also has a number of retail cannabis initiatives in Western Canada.Â Â GTEC currently holds a 100% interest in GreenTec Bio-Pharmaceuticals Corp., Tumbleweed Farms Corp., Falcon Ridge Naturals Ltd., Alberta Craft Cannabis Inc., Grey Bruce Farms Inc., Zenalytic Laboratories Ltd. and Spectre Labs Inc.Â GTEC is a publicly-traded corporation based in Kelowna, British Columbia.Â The Company’s shares are listed on the TSX Venture Exchange and OTC Pink Sheets.

About Namaste Technologies Inc.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (604) 355-6100

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-announces-supply-agreement-with-gtec-holdings-300702533.html

SOURCE Namaste Technologies Inc.

Tags: #smallcapstocks, CSE, MMJ, Vapes, Vaping
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Supply Agreement with GTEC Holdings $GTEC.ca $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Namaste $N.ca $NXTTF Announces Approval of NamasteMD Android App and Accelerates Patient Acquisition in Anticipation of Sales License $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:03 AM on Friday, August 24th, 2018

Announced that the Company has received official approval of the latest version of its NamasteMD cannabis telemedicine App for Google Android devices,
Live in the Google Play store as of 8 AM EST August 23rd, 2018

VANCOUVER, Aug. 24, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has received official approval of the latest version of its NamasteMD (“NamasteMD.com“) cannabis telemedicine App for Google Android devices, which is live in the Google Play store as of 8 AM EST August 23rd, 2018. Approximately 50% of mobile phone users in Canada use Android devices. With the new launch of the apps on both iOS and Android platforms, NamasteMD can now facilitate online patient consultations, free of charge, within 15 minutes from sign-up on the App. The Company anticipates launching real-time consultations through NamasteMD within the next 10 days. Further to the Company’s Aug 22nd news release, NamasteMD has achieved over 14,000 registered users, representing a 130% increase over a 2-month period. The Company anticipates significant acceleration in conversion rates with additional exposure through the Google Play store.

Namaste has developed Canada’s first fully-compliant medical cannabis patient portal, available on iPhone or Android devices, which allows Namaste to acquire patients faster and at a lower cost in comparison with other Licensed Producers. Patients acquired through NamasteMD have access to purchase medical cannabis through Namaste’s cultivation partners (“Licensed Producers). Under the terms of various Educational Service Agreements (“Service Agreements”), Namaste collects between 15-20% of the gross revenue derived from patient purchasing through referrals to Licensed Producers under NamasteMD. Namaste is presently partnered with over 10 Licensed Producers.

With Namaste’s medical cannabis “sales-only” license imminent, the Company anticipates a sharp increased revenue and margin with Cannmart booking full revenue amounts from patient ordering and the Company will aim to maintain a minimum of a 50% gross margin on cannabis products sold directly on its website.

Namaste operates over 30 e-commerce sites across the globe with over 1.5 Million customers. Integration of cannabis and consumable sales including CBD products into Namaste’s platform will propel the Company to become a global leader in the online retail of all things cannabis. The Company will launch the same strategy in leveraging its consumer databases along with its innovative technology platforms to expand NamasteMD and Cannmart’s model into international markets where Namaste maintains significant market share.

Management Commentary

Sean Dollinger, President, and CEO of Namaste comments: “We’re very pleased to announce the launch of NamasteMD in the Google Play Store. We have been overwhelmed by the acceleration rate of our registered users and anticipate seeing even faster growth having now received approval from Google. With approximately 50% of mobile phone users operating on Google Android devices, we are expecting to see patient numbers accelerate even quicker than we have experienced so far. NamasteMD is a key component of our strategy in developing Canada’s largest medical cannabis patient database and in launching cannabis sales in Canada and abroad. While the process of acquiring a medical cannabis prescription and onboarding with a Licensed Producer typically can take several days or weeks, Namaste will offer a fully-integrated platform for new patients to consult with a nurse practitioner and immediately be connected with Cannmart to order their product. We believe in bringing value to our patients through technological innovation and aim to set the highest standard for patient care going forward.”

About Namaste Technologies Inc.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-announces-approval-of-namastemd-android-app-and-accelerates-patient-acquisition-in-anticipation-of-sales-license-300701963.html

Tags: #smallcapstocks, $TSXV, CSE, MMJ, NamasteMD, Vapes, Vaping
Posted in Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Approval of NamasteMD Android App and Accelerates Patient Acquisition in Anticipation of Sales License $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Provides Extension to North Bud Farms $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:30 AM on Friday, August 3rd, 2018

Announced that the company has provided an extension to North Bud Farms Inc
Tetra and North Bud Farms Inc. are working diligently to finalize the transaction and to this end Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc

ORLEANS, Ontario, Aug. 03, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that the company has provided an extension to North Bud Farms Inc.Â Tetra and North Bud Farms Inc. are working diligently to finalize the transaction and to this end Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the final receipt of North Budâ€™s prospectusâ€™.Â As one of the closing conditions to the sale these documents must now be submitted by August 31, 2018.Â Upon final receipt of North Budâ€™s prospectus and meeting the requirements requested by the Ontario Securities Commission, Tetra will announce the record date and begin the process with the distribution of the dividend which must be finalized before listing the shares of North Bud Farms Inc.

AboutÂ Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at:Â www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Tags: #smallcapstocks, $TSXV, CBD, CSE, Hemp, MMJ
Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Provides Extension to North Bud Farms $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Announces Quarterly Sales of $4.1M Representing 32% Quarter-Over-Quarter Growth $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 10:56 AM on Monday, July 23rd, 2018

Company’s net revenues for the three months ended May 31, 2018 were $4.1 million (2017 â€“ $3.1 million),
- which is an increase of $1.0 million or 32% as compared to the three months ended May 31, 2017.
The increase in net revenues during the third quarter of 2018 was primarily due to organic growth in the Company.

VANCOUVER, July 23, 2018 -Â Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE: N), (FRANKFURT: M5BQ), (OTCMKTS: NXTTF) is pleased to announce the filing of its unaudited quarterly financial statements, management’s discussion and analysis and certification of the quarterly filings for the third quarter of fiscal 2018. The statements for the period can be accessed on the Company’s SEDAR profile at www.sedar.com.

The Company’s net revenues for the three months ended May 31, 2018 were $4.1 million (2017 â€“ $3.1 million), which is an increase of $1.0 million or 32% as compared to the three months ended May 31, 2017. The increase in net revenues during the third quarter of 2018 was primarily due to organic growth in the Company.

The Company’s net revenues for the nine months ended May 31, 2018 were $14.6 million (2017 â€“ $7.1 million), which is an increase of $7.5 million or 106% as compared to the nine months ended May 31, 2017 despite having divested the Company’s U.S. business in December 2017. The increase in net revenues during the nine months ended May 31, 2018 was primarily due to revenue growth from EDIT domains and Australian Vaporizers. EDIT domains were acquired in October 2016 and Australian Vaporizers was acquired in March 2017.

Revenues by country
	*For three months ended*		*For nine months ended*
Country	May 31, 2018	May 31, 2017- Restated		May 31, 2018	May 31, 2017- Restated

United Kingdom	1,168,003	809,957		3,748,179	2,095,184
Australia	1,291,727	1,047,628		3,941,927	1,217,883
United States of America	5,075	445,834		1,822,844	1,883,363
Brazil	384,467	166,409		1,119,790	368,923
Canada	566,781	117,763		1,601,228	276,986
Germany	204,250	84,189		754,738	140,286
New Zealand	85,919	79,467		262,117	288,784
Ireland	88,133	55,998		244,113	143,262
Israel	16,704	56,037		116,450	104,640
Other	251,162	227,923		1,015,775	566,188

Total	4,062,221	3,091,205		14,627,161	7,085,499

The majority of revenues were generated by several key markets. For the three and nine months ended May 31, 2018, the top five revenue earning countries generated 90% and 84% of revenues, respectively. For the three and nine months ended May 31, 2017, the top five revenue earning countries generated 87% and 87% of revenues, respectively.

The Company’s cost of sales for the three months ended May 31, 2018 were $3.2 million (2017 â€“ $2.4 million), which resulted in a gross profit of $0.9 million (2017 â€“ $0.7 million). The gross profit increased by $0.2 million or 31% primarily due to the growth in revenue. The gross profit margin of 21% was comparable to the gross margin of 22% in the same period last year.

Management is focused on the expansion of its globally diversified platform of e-commerce websites to reinforce its position as “Your Everything Cannabis Store™” by selling all cannabis-related products ranging from vaporizers and smoking accessories to CBD products, as well as personal growing and extraction equipment.

The Company is actively engaged with Health Canada in relation to Namaste’s wholly owned subsidiary and Access to Cannabis for Medical Purposes Regulations (“ACMPR”) Licensed Producer, Cannmart, which awaits its medical cannabis “sales-only” license.

Namaste acquired Findify AB (“Findify” or “Findify.io”) during its third quarter. Findify is a leading artificial intelligence (“AI”) software company, which uses machine learning algorithms to track users’ behavior online in real-time, and provide a more personalized buying experience. Findify’s technology works to provide better recommendations to consumers and to optimize search results that are customized to the user’s choice patterns. The Company is working with Findify’s management team to develop a marketing and roll-out strategy that will introduce the technology across Namaste’s e-commerce platform and offer it to other companies in the industry.

Management Commentary

Kenneth Ngo, CFO of Namaste comments: “We are pleased to see a 32% increase in quarterly revenue compared to the same period last year, due to organic growth in the Company’s vaporizer business. The Q3 results are very encouraging especially considering that Namaste divested its U.S assets and revenue which accounted for 14.4% of the total revenue during Q3 of 2017.

The acquisition of Findify AB in the quarter was the largest acquisition to date in the history of Namaste.Â This acquisition will bring significant value to Namaste and its shareholders by accelerating the Company’s growth in revenue.”

Sean Dollinger, President and CEO of Namaste comments: “Our Q3 financial results show continuous growth year-on-year, and this quarter also represented major milestones for the Company including the acquisition of Findify, which we believe will drive significant revenue going forward by increasing customer conversion and retention. We are working on several integrations of Findify’s technology in real-world applications of AI within the cannabis industry that will be impactful in understanding patients’ needs and in personalizing their online experience. Namaste will continue to focus and developing innovative technology which drives revenue and brings long term value to the company. Our quarterly results are very encouraging and have not factored in any cannabis sales or the sale of CBD products in international markets, which we are highly focused on presently. We’re looking forward to seeing impactful results in these new sales channels in the near future.”

About Namaste Technologies Inc.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Tags: #smallcapstocks, $TSXV, CSE, MMJ, Vapes, Vaping
Posted in All Recent Posts, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Quarterly Sales of $4.1M Representing 32% Quarter-Over-Quarter Growth $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posts Tagged ‘MMJ’

PPP001 and PPP005 Eligible for Marketing Approval

Categories